- active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
Italy · United Kingdom - active not recruitingPHASE1, PHASE2
First-in-Human Study of ICT01 in Patients With Advanced Cancer
This study is testing a new drug called ICT01, sometimes with another drug called pembrolizumab (Keytruda), for people with advanced cancers. It aims to find the right dose and see how well it works and if it's safe. It's for adults with various solid tumours or blood cancers.
United States · Belgium · France - recruitingPHASE1, PHASE2
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
This study is testing a new experimental drug, ATTR-01, for people with certain solid cancers. It uses a modified common cold virus to target cancer cells and help your immune system fight them.
Spain · United Kingdom - recruitingPHASE1, PHASE2
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
This study is testing a new medicine, CRB-701, for people with certain advanced solid cancers. It aims to find a safe and effective dose, and see which cancers it can treat. Participants will receive the medicine and have tests to check how it works.
United States · France · Italy - enrolling by invitationPHASE1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
This study helps us understand the long-term safety of new treatments for certain cancers like leukemia and lymphoma. People who have already been in an earlier drug trial for these conditions will continue to be monitored to see how they respond over time.
Australia · Belgium · France - active not recruitingPHASE1
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
This study is testing a new medicine, KIN-2787, alone or with another drug, binimetinib, for adults with certain advanced cancers. It aims to see how safe the drug is, if it works, and how the body handles it. It's for people whose cancer has specific genetic changes (BRAF/NRAS mutations).
United States · Australia · China - active not recruitingPHASE1
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
This study is testing a new medicine, IMA401, for people with advanced cancers that have come back or haven't responded to other treatments. We want to see if it's safe, how well people tolerate it, and if it can help shrink tumours, either alone or with another cancer drug called pembrolizumab.
Germany - recruitingPHASE1, PHASE2
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
This study is testing a new medicine, IMA402, for adults with advanced or returning solid cancers that haven't responded to other treatments. We want to see if it's safe, what dose works best, and if it can help shrink tumours.
Germany · Netherlands - active not recruitingPHASE1, PHASE2
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
This study is testing a new ‘genetic vaccine’ alongside an existing cancer drug (Keytruda®) for adults with certain advanced cancers. It aims to see if the combination is safe, how the body reacts to it, and if it helps shrink tumours.
United States · Belgium · Canada - recruitingPHASE1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
This study is testing a new medicine, TYRA-430, for people with advanced liver cancer or other advanced solid tumours that have specific gene changes. Researchers want to see if it's safe and if it can help shrink tumours.
United States · Canada · South Korea - active not recruitingPHASE1, PHASE2
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
This study is looking at a new drug called visugromab (CTL-002) for people with advanced cancer. It aims to see how safe the drug is, what doses work best, and if it can help fight different types of solid tumours, sometimes used with another cancer medicine.
Germany · Spain · Switzerland - recruitingPHASE1, PHASE2
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This study is testing a new drug, BI-1206, with an existing cancer treatment, pembrolizumab, for adults with advanced solid tumours. It aims to find the safest dose and see if this combination can help people whose cancer has progressed or who haven't had previous treatment for advanced disease.
United States · Georgia · Germany - active not recruitingPHASE1, PHASE2
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This study is looking at a new medicine called HST-1011, sometimes with another medicine called cemiplimab, for adults with advanced solid cancers. It's for people whose cancer hasn't responded to previous treatments or has come back after them.
United States · Canada · Spain